RNA, U7 small nuclear 128 pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU7-128P profile across patient tissues and cancer cell-line models. RNU7-128P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU7-128P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, RNU7-128P RNA expression shows 11,587 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUSC, and LSCC as cancer lineages where RNU7-128P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-128P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-128P survival associations across molecular data types. RNU7-128P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-128P RNA expression–survival associations across cancer types. High RNU7-128P expression shows unfavorable associations in KIRC, ACC, CESC, THCA and SARC, but favorable associations in GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU7-128P RNA expression.
This table summarizes RNU7-128P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-128P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-128P shows lower tumor expression in THCA and higher tumor expression in LUSC, COAD and BRCA. The LUSC box plot shows higher RNU7-128P RNA expression in tumor versus normal tissue (log2 FC = +0.223, t-test p = .001).
This table shows molecular features associated with RNU7-128P in patient tissues and cancer cell lines. In patient samples, RNU7-128P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
